Ovid Therapeutics Inc. (NASDAQ:OVID) Receives Consensus Recommendation of “Moderate Buy” from Brokerages
Ovid Therapeutics Inc. (NASDAQ:OVID – Get Free Report) has received a consensus recommendation of “Moderate Buy” from the six analysts that are presently covering the stock, Marketbeat.com reports. Two equities research analysts have rated the stock with a hold rating and four have assigned a buy rating to the company. The average twelve-month price target […]
More Stories
GoDaddy (NYSE:GDDY) Earns “Buy” Rating from Benchmark
Benchmark reissued their buy rating on shares of GoDaddy (NYSE:GDDY – Free Report) in a report issued on Tuesday, Benzinga...
Wells Fargo & Company Cuts Rivian Automotive (NASDAQ:RIVN) Price Target to $11.00
Rivian Automotive (NASDAQ:RIVN – Free Report) had its target price decreased by Wells Fargo & Company from $15.00 to $11.00...
Wells Fargo & Company Boosts Rollins (NYSE:ROL) Price Target to $56.00
Rollins (NYSE:ROL – Free Report) had its target price raised by Wells Fargo & Company from $54.00 to $56.00 in...
Allstate (NYSE:ALL) Given New $216.00 Price Target at UBS Group
Allstate (NYSE:ALL – Free Report) had its price target lifted by UBS Group from $215.00 to $216.00 in a report...
Devon Energy (NYSE:DVN) Earns Hold Rating from Benchmark
Benchmark restated their hold rating on shares of Devon Energy (NYSE:DVN – Free Report) in a research note issued to...
Barclays Raises General Motors (NYSE:GM) Price Target to $64.00
General Motors (NYSE:GM – Free Report) (TSE:GMM.U) had its target price lifted by Barclays from $60.00 to $64.00 in a...